The latest study ascertained that reduced m6A modification by knocking out methyltransferase genes, Mettl3 and Mettl14, enhanced response to PD-1 inhibitors in murine colorectal carcinoma cell line CT26 [29]. This evidence concerns the gene METTL14 and colorectal carcinoma.